|Day's Range||31.20 - 31.38|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.48|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.
Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.
Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday. The designation covers Venclexta ...